Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan II plus 5-fluorouracil/leucovorin and oxaliplatin for advanced pancreatic cancer
ChiCTR2500100512Phase 4Recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of nanoliposomal irinotecan, fluorouracil, folinic acid and oxaliplatin, sponsored by Ningbo No. 2 Hospital. Started Apr 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic acidoxaliplatin
Beyond the preview
Go deeper on ChiCTR2500100512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100512.